Study guide

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan

Key Takeaways Explain This Topic AI

The annual well-woman visit integrates age-tailored health history, individualized physical examination, immunizations, and preventive screening across four core developmental phases: adolescence, reproductive age, perimenopause, and postmenopause.

Sexual history taking should be structured around the CDC 5 Ps: Partners, Practices, Protection from STIs, Past history of STIs, and Pregnancy intention, using open-ended, nonjudgmental language.

Guidance on screening pelvic exams differs: ACOG (Committee Opinion 754) advises pelvic exams when history or symptoms indicate them and shared decision-making for asymptomatic patients, while the USPSTF finds the evidence insufficient (I statement).

Adult immunization priorities for women include HPV vaccination through age 26 (and shared clinical decision-making ages 27–45), Tdap during each pregnancy between 27 and 36 weeks gestation, universal hepatitis B vaccination for adults aged 19–59, and seasonal maternal RSV immunization at 32–36 weeks.

Routine primary care preventive screening includes universal colorectal cancer screening starting at age 45, diabetes screening starting at age 35 for individuals with overweight or obesity, and DEXA bone density screening at age 65, or earlier when a formal risk tool such as FRAX or OST shows increased fracture risk in a postmenopausal woman (USPSTF 2025).

Last updated: October 2026

Lifespan Care & The Annual Well-Woman Visit

The annual well-woman visit provides a dedicated platform to deliver preventive screening, counsel on reproductive choices, administer immunizations, and optimize chronic conditions. Priorities evolve across four core lifespan epochs:

Adolescence (Ages 13–21): The initial visit should occur between ages 13 and 15 to build rapport, assess pubertal development, and evaluate psychosocial health using HEEADSSS (Home, Education, Eating, Activities, Drugs, Sexuality, Suicide, Safety). Clinicians must clarify confidentiality boundaries. Routine speculum and bimanual exams are not indicated in asymptomatic adolescents, even when initiating contraception.

Reproductive Age (Ages 21–39): Care centers on reproductive life planning, contraception, preconception counseling (daily folic acid: 0.4 mg average risk, 4.0 mg high risk), intimate partner violence (IPV) screening, and cervical cancer screening beginning at age 21.

Perimenopause & Menopausal Transition (Ages 40–64): Focus shifts to managing ovulatory shifts, vasomotor symptoms, abnormal bleeding, and metabolic risks. Colorectal cancer screening initiates at age 45 alongside biennial screening mammography and cardiovascular risk profiling.

Postmenopause & Older Adults (Ages 65+): Priorities center on functional mobility, fall prevention, cognitive screening, genitourinary syndrome of menopause (GSM), polypharmacy review, and universal osteoporosis screening with central DEXA at age 65.

Health History & The 5 Ps of Sexual Health

Obtaining an accurate, trauma-informed sexual and reproductive history requires open-ended communication. The CDC structures this assessment around the 5 Ps :

Domain Core Clinical Inquiries Key Objectives

1. Partners "Do you have sex with men, women, or both? In the past 12 months, how many partners have you had?" Identifies transmission networks and directs anatomical testing sites (cervical, pharyngeal, rectal).

2. Practices "What sexual contact do you have: vaginal, anal, or oral? Do you use sex toys or barrier devices?" Directs extragenital NAAT screening and evaluates tissue trauma risk.

3. Pregnancy Intention "What are your plans regarding pregnancy? What methods do you use to prevent pregnancy?" Assesses pregnancy intention, contraceptive efficacy, and preconception optimization needs.

4. Protection from STIs "How do you protect against STIs and HIV? How consistently do you use condoms?" Evaluates barrier consistency and determines eligibility for HIV pre-exposure prophylaxis (PrEP).

5. Past History of STIs "Have you or any partners ever been diagnosed with or treated for an STI?" Flags risk for recurrent infections, pelvic inflammatory disease (PID), and tubal scarring.

Note

Clinicians increasingly evaluate a sixth "P"— Pleasure —assessing dyspareunia, sexual satisfaction, and pelvic floor function during the well-woman visit.

Physical Examination Guidelines & Pelvic Exam Debate

A comprehensive exam includes vital signs, BMI, thyroid assessment, cardiopulmonary auscultation, abdominal palpation, and age-appropriate breast and pelvic examinations.

Asymptomatic Screening Pelvic Exam Controversy

ACOG (Committee Opinion 754, 2018): Recommends pelvic examinations when indicated by medical history or symptoms. For asymptomatic, nonpregnant patients, whether to perform an external or internal exam is a shared decision. ACOG acknowledges the exam does not screen for ovarian cancer, while noting possible benefits such as vulvar inspection and patient reassurance.

USPSTF: Issues an I statement (insufficient evidence) regarding routine screening pelvic exams in asymptomatic, nonpregnant women. Bimanual palpation exhibits sensitivity under 30% and very low positive predictive value for early ovarian cancer, triggering unnecessary testing and surgery.

Indications for Diagnostic Pelvic Examination

A complete speculum and bimanual exam is mandatory for clinical signs: unexplained pelvic pain, abnormal bleeding, dyspareunia, abnormal discharge, suspected prolapse/mass, cervical cytology collection, and IUD insertion or string checks.

Adult & Maternal Immunization Protocols

Immunization records must be audited at every preventive encounter:

Human Papillomavirus (HPV; 9-valent): Routine at age 11–12 (can start at 9); catch-up through age 26; shared decision-making for ages 27–45. FDA-labeled dosing is 2 doses (0, 6–12 months) if started before age 15 and 3 doses (0, 1–2, 6 months) if started at 15 or older or if immunocompromised; an interrupted series is never restarted. In January 2026 CDC's revised childhood schedule moved to a single HPV dose (a change not voted by ACIP), so confirm the current federal and professional-society schedule before counseling.

Tdap: Routine booster every 10 years. Administer one dose during each pregnancy between 27 and 36 weeks gestation to maximize transplacental IgG pertussis antibodies to the fetus.

Influenza: Annually for all persons ≥6 months. Inactivated (IIV) or recombinant (RIV) vaccines are safe during any trimester. Live attenuated vaccine (LAIV) is contraindicated in pregnancy .

MMR & Varicella: Live attenuated vaccines are contraindicated in pregnancy . Avoid pregnancy for 28 days (4 weeks) post-vaccination. Administer postpartum if non-immune.

Hepatitis B: Universal vaccination for all adults aged 19–59, and adults ≥60 with risk factors. Universal HBsAg screening is standard in every pregnancy.

Pneumococcal: Since October 2024, ACIP recommends a pneumococcal conjugate vaccine for all adults aged 50 and older (and adults 19–49 with risk conditions): PCV20 or PCV21 alone, or PCV15 followed by PPSV23 one year later.

Herpes Zoster (Shingrix): Recombinant vaccine (2 doses at 0, 2–6 months) for adults aged 50+ and immunocompromised adults aged 19+.

RSV (Abrysvo): Maternal bivalent vaccine given at 32 to 36 weeks gestation from September through January to protect infants from severe lower respiratory tract disease. A single adult RSV dose is recommended for everyone aged 75 and older and for adults 50–74 at increased risk (chronic heart, lung, kidney, or metabolic disease, immunocompromise, or nursing-home residence).

Note

Federal vaccine recommendations changed repeatedly during 2025–2026 (for example, CDC moved COVID-19 vaccination to individual-based decision-making). ACOG published its own 2026 Maternal Immunization Schedule, endorsed by NPWH and 12 other organizations. It continues to recommend Tdap, inactivated influenza, COVID-19, and seasonal RSV (Abrysvo) vaccination in pregnancy.

Routine Preventive Screening Schedule

Screening Domain Target Population Modality Frequency & Clinical Guidance

Lipids Adults aged 20+ (2026 ACC/AHA guideline) Fasting or non-fasting lipid profile; lipoprotein(a) at least once Repeat every 4–6 years at average risk; estimate 10-year risk with PREVENT-ASCVD at ages 30–79.

Diabetes / Prediabetes Asymptomatic adults aged 35–70 with BMI ≥25 (≥23 in Asian Americans) Fasting glucose, HbA1c, or 2-hr OGTT Every 3 years. Screen earlier if high-risk (PCOS, gestational diabetes history).

Colorectal Cancer Average-risk adults aged 45 to 75 Colonoscopy, annual FIT, or sDNA-FIT Colonoscopy every 10 years, annual FIT, or sDNA-FIT every 1–3 years.

Osteoporosis (DEXA) All women aged 65+; postmenopausal women <65 with elevated risk Central DEXA (femoral neck and spine) Universal at age 65 (USPSTF 2025, grade B). If postmenopausal and under 65, screen when a formal clinical risk tool (FRAX, OST, or ORAI) shows increased risk; the 2025 statement sets no single FRAX cutoff.

Lung Cancer Adults aged 50–80 with ≥20 pack-years who smoke now or quit within 15 years Annual low-dose CT Stop after 15 smoke-free years or when health limits benefit (USPSTF 2021).

Tip

In postmenopausal women under age 65, first look for risk factors (low body weight, parental hip fracture, smoking, excess alcohol, glucocorticoid use), then apply a validated tool such as FRAX or OST. Older USPSTF statements compared a woman's FRAX risk with that of an average 65-year-old White woman (9.3% in 2011, 8.4% in 2018); the 2025 statement names no threshold.

Loading diagram... Well-Woman Preventive Screening Timeline Across the Lifespan